{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The study was terminated early due to discontinuation of development of modakafusp alfa for strategic reasons. The November 7 2024 data cut comprises the final full dataset for safety and efficacy."},"pointOfContact":{"email":"USMedInfo@tevapharm.com","organization":"Teva Branded Pharmaceutical Products R&D LLC","phone":"1-888-483-8279","title":"Study Director"}}